Readmission due to driveline infection can be predicted by new score by using serum albumin and body mass index during long-term left ventricular assist device support

Journal of Artificial Organs

Volumn 18, Issue 2, 2015, Pages 120-127

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Nitta, Daisuke ^b   Inaba, Toshiro ^b   Maki, Hisataka ^b   Hatano, Masaru ^b   Kinoshita, Osamu ^a   Nawata, Kan ^a   Kyo, Shunei ^a   Ono, Minoru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cardiac cachexia; Nutrition; Quality of life; VAD

Indexed keywords

ALBUMIN; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; CONTROLLED STUDY; DRIVELINE INFECTION; FEMALE; FOLLOW UP; HEART FAILURE; HIGH RISK POPULATION; HOSPITAL READMISSION; HUMAN; IMPLANTATION; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; UNIVARIATE ANALYSIS; ADVERSE EFFECTS; AGED; HEART ASSIST DEVICE; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROSTHESIS-RELATED INFECTIONS; QUALITY OF LIFE; RISK FACTOR; SURGICAL WOUND INFECTION;

ADULT; AGED; BODY MASS INDEX; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; PREDICTIVE VALUE OF TESTS; PROSTHESIS-RELATED INFECTIONS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SURGICAL WOUND INFECTION;

EID: 84929946817     PISSN: 14347229     EISSN: 16190904     Source Type: Journal    
DOI: 10.1007/s10047-015-0816-2     Document Type: Article

References (34)

1. Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg. 2001;122:1186–95.
2. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–43.
3. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.
4. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312–21.
5. Imamura T, Kinugawa K, Shiga T, et al. Novel risk scoring system with preoperative objective parameters gives a good prediction of 1-year mortality in patients with a left ventricular assist device. Circ J. 2012;76:1895–903.
6. Hannan MM, Husain S, Mattner F, et al. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant. 2011;30:375–84.
7. Zierer A, Melby SJ, Voeller RK, et al. Late-onset driveline infections: the Achilles’ heel of prolonged left ventricular assist device support. Ann Thorac Surg. 2007;84:515–20.
8. Holman WL, Naftel DC, Eckert CE, Kormos RL, Goldstein DJ, Kirklin JK. Durability of left ventricular assist devices: interagency registry for mechanically assisted circulatory support (INTERMACS) 2006–2011. J Thorac Cardiovasc Surg. 2013;146:437–41 e1.
9. Oz MC, Gelijns AC, Miller L, et al. Left ventricular assist devices as permanent heart failure therapy: the price of progress. Ann Surg. 2003;238:577–83 (discussion 83-5).
10. Monkowski DH, Axelrod P, Fekete T, Hollander T, Furukawa S, Samuel R. Infections associated with ventricular assist devices: epidemiology and effect on prognosis after transplantation. Transpl Infect Dis. 2007;9:114–20.
11. Toda K, Yonemoto Y, Fujita T, et al. Risk analysis of bloodstream infection during long-term left ventricular assist device support. Ann Thorac Surg. 2012;94:1387–93.
12. Sharma V, Deo SV, Stulak JM, et al. Driveline infections in left ventricular assist devices: implications for destination therapy. Ann Thorac Surg. 2012;94:1381–6.
13. De Luis DA, Culebras JM, Aller R, Eiros-Bouza JM. Surgical infection and malnutrition. Nutr Hosp. 2014;30:509–13.
14. Goldstein DJ, Naftel D, Holman W, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant. 2012;31:1151–7.
15. Raymond AL, Kfoury AG, Bishop CJ, et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J. 2010;56:57–60.
16. Bomholt T, Moser C, Sander K, et al. Driveline infections in patients supported with a HeartMate II: incidence, aetiology and outcome. Scand Cardiovasc J. 2011;45:273–8.
17. Vega JD, Poindexter SM, Radovancevic B, et al. Nutritional assessment of patients with extended left ventricular assist device support. ASAIO Trans. 1990;36:M555–8.
18. Leeper B. Impact of obesity on care of postoperative coronary bypass patients. Crit Care Nurs Clin North Am. 2009;21:369–75 vi.
19. Martin SI, Wellington L, Stevenson KB, et al. Effect of body mass index and device type on infection in left ventricular assist device support beyond 30 days. Interact CardioVasc Thorac Surg. 2010;11:20–3.
20. Butler J, Howser R, Portner PM, Pierson RN 3rd. Body mass index and outcomes after left ventricular assist device placement. Ann Thorac Surg. 2005;79:66–73.
21. Coyle LA, Ising MS, Gallagher C, et al. Destination therapy: one-year outcomes in patients with a body mass index greater than 30. Artif Organs. 2010;34:93–7.
22. Arques S, Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. J Card Fail. 2011;17:451–8.
23. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 1999;115:836–47.
24. Berry C, Clark AL. Catabolism in chronic heart failure. Eur Heart J. 2000;21:521–32.
25. Mano A, Fujita K, Uenomachi K, et al. Body mass index is a useful predictor of prognosis after left ventricular assist system implantation. J Heart Lung Transplant. 2009;28:428–33.
26. Kato TS, Kitada S, Yang J, et al. Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation. Am J Cardiol. 2013;112:1484–8.
27. Siegenthaler MP, Martin J, Pernice K, et al. The Jarvik 2000 is associated with less infections than the HeartMate left ventricular assist device. Eur J Cardiothorac Surg. 2003;23:748–54 (discussion 54–5).
28. Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg. 2010;90:1270–7.
29. Hieda M, Sata M, Seguchi O, et al. Importance of early appropriate intervention including antibiotics and wound care for device-related infection in patients with left ventricular assist device. Transplant Proc. 2014;46:907–10.
30. Nienaber JJ, Kusne S, Riaz T, et al. Clinical manifestations and management of left ventricular assist device-associated infections. Clin Infect Dis. 2013;57:1438–48.
31. Holdy K, Dembitsky W, Eaton LL, et al. Nutrition assessment and management of left ventricular assist device patients. J Heart Lung Transplant. 2005;24:1690–6.
32. Abicht T, Gordon R, Meehan K, Stosor V, McCarthy P, McGee E Jr. Complex HeartMate II infection treated with pump exchange to HeartWare HVAD. ASAIO J. 2013;59:188–92.
33. Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato EF. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980;139:160–7.
34. Aggarwal A, Kumar A, Gregory MP, et al. Nutrition assessment in advanced heart failure patients evaluated for ventricular assist devices or cardiac transplantation. Nutr Clin Pract. 2013;28:112–9.